Encycle Therapeutics, a Toronto-based drug discovery company that enables the synthesis of a new type of constrained peptide called “nacellins,” has entered a research collaboration with Pfizer. The companies will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s nacellin library, that act on an undisclosed therapeutic target.   Nacellins are a type of peptide macrocycle that can often exhibit higher permeability, solubility, and ...